RxDoctor Payments Data

Sara Covert, NP

Nurse Practitioner · Indianapolis, INNPI 1780292995

Payments from drug & device makers

$3,551in general payments, 2019–2025

Across 188 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$425
  • Novartis$422
  • Pharmacyclics LLC, An Abbvie Company$259
  • Johnson & Johnson$213
  • Incyte Corporation$196
  • Merck$183
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$3,14088%
  • Education$41112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,551 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$52,925
Medicare patients
188
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate16$355,423
XtandiEnzalutamide15$208,451
BrukinsaZanubrutinib14$183,925
CalquenceAcalabrutinib Maleate12$166,252
EliquisApixaban42$38,429
XareltoRivaroxaban36$38,010
Enoxaparin Sodium20$10,774
Letrozole54$1,216
Acyclovir70$1,149
Ursodiol17$918
Ondansetron Hcl37$673
Potassium Chloride27$563
Prednisone91$407
Prochlorperazine Maleate33$393
Escitalopram Oxalate28$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$56$355,42316 claims
Astellas Pharma US IncXtandi$58$208,45115 claims
Beigene USA, Inc.Brukinsa$73$183,92514 claims
AstraZenecaCalquence$21$166,25212 claims
PfizerEliquis$26$38,42942 claims
Johnson & JohnsonXarelto$213$38,01036 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$13$1,14970 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →